Search J Rheum

Advanced Search

Home

Current Issue

Archives

Guidelines for Authors & Reviewers

Classified Ads

Links

Search PubMed

Subscriptions

Subscriber Registration

Guidelines for Website Users

JRheum Update Service

Contact Info


Download PDF


View Table of Contents

Prospective Assessment of Body Weight, Body Composition, and Bone Density Changes in Patients with Spondyloarthropathy Receiving Anti-Tumor Necrosis Factor-α Treatment

KARINE BRIOT, LAURE GOSSEC, SAM KOLTA, MAXIME DOUGADOS, and CHRISTIAN ROUX

ABSTRACT.

Objective.
To determine the changes in body weight, body composition, and bone density in patients with spondyloarthropathy (SpA) receiving anti-tumor necrosis factor-a (TNF-a) treatment.

Methods. One hundred six patients with SpA (80 men, 26 women) aged 20-71 years were included in a 2-year prospective open study. Fifty-nine patients received infliximab (3 or 5 mg/kg/infusion each 6 or 8 weeks); and 47 patients received etanercept (25 mg twice a week) because of persistent active disease despite an optimal treatment, according to ASsessments in Ankylosing Spondylitis Working Group criteria. Body weight, total body composition (lean mass, fat mass), and spine and femoral bone mineral density (BMD; dual-energy x-ray absorptiometry) were measured at baseline and at 1 and 2 years.

Results. There was a significant increase in body weight after 1 year (2.2 ± 3.9 kg, i.e., 3.4%; p < 0.0001) and 2 years (2.2 ± 4.7 kg, 3.5%; p < 0.0001), mostly due to a significant gain in fat mass at 1 year (1.4 ± 2.6 kg, 12.1%; p < 0.0001) and 2 years (1.5 ± 3.1 kg, 14.5%, p < 0.0001). Gain in lean mass was also significant at 1 year (0.8 ± 2.2 kg, 1.9%; p < 0.0001) and 2 years (0.9 ± 2.5 kg, 2%; p < 0.0001). At 2 years, lumbar spine and femur BMD increased: +5.8 ± 13% (p < 0.0001) and +2.26 ± 4.5% (p = 0.001), respectively.

Conclusion. This 2-year prospective study showed a significant increase in body weight at 1 year and 2 years, mostly due to a gain in fat mass and a significant increase in BMD, in patients with SpA receiving anti-TNF-a treatment. (J Rheumatol First Release Mar 15 2008)

Key Indexing Terms:

ANTI-TUMOR NECROSIS FACTOR
SPONDYLOARTHROPATHY
OSTEOPOROSIS
BODY COMPOSITION
CACHEXIA


From Paris-Descartes University, Medicine Faculty, Cochin Hospital, Paris, France.

K. Briot, MD; L. Gossec, MD; S. Kolta, MD; M. Dougados, MD, PhD; C. Roux, MD, PhD, Paris-Descartes University.

Address reprint requests to Dr. K. Briot, Paris-Descartes University, Medicine Faculty, UPRES-EA 4058, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France. E-mail: karine.briot@cch.aphp.fr

Accepted for publication December 16, 2007.



Return to First Release Table of Contents



© The Journal of Rheumatology Publishing Company Limited.
All rights reserved.